Appendix Table C17Trial description: oral selective antihistamine versus oral decongestant

Author, YearLocation, Site(s)Enrollment/Treatment DurationFunding/Author Industry DisclosuresNInclusion CriteriaExclusion CriteriaRescue Medication UseObjective DiagnosisRun in PeriodPollen CountPatient BlindingAssessor Blinding
Bronsky, 1995N. America
Multiple
Fall 1989
2 weeks
Industry
Yes
437Minimum SAR severity and durationSAR meds
Other meds
Chronic asthma
Pregnancy
Infection
No
Chervinsky, 2005N. America
Multiple
2 weeksNR
Yes
436Minimum SAR severity and durationSAR meds
Pregnancy
Infection
No
Grosclaude, 1997Europe
Multiple
March1992
2 weeks
NR
Yes
454Minimum SAR severity and durationSAR meds
Other meds
Pregnancy
Infection
Deformities
Yes
Grubbe, 2009N. America
Multiple
2.1 weeksIndustry
Yes
398Minimum SAR severity and durationSAR meds
Chronic asthma
Pregnancy
Infection
Deformities
No
Pleskow, 2005N. America
Multiple
2000
2 weeks
Industry
Yes
749Minimum SAR severity and durationSAR meds
Pregnancy
Infection
Deformities
No
Schenkel, 2002N.America
Multiple
2.1 weeksIndustry
NR
682Minimum SAR durationSAR meds
Chronic asthma
Pregnancy
No
Sussman, 1999N.America
Multiple
2.6 weeksIndustry
Yes
436Minimum SAR severitySAR meds
Pregnancy
Infection
No

N = Patients randomized to comparator groups of interest; NR = not reported; SAR = seasonal allergic rhinitis.

a

+, -, or NR indicates whether FDA-recommended washout periods were required (+), were not required (-), or were not reported (NR) for restricted SAR medications prior to trial entry.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.